Zobrazeno 1 - 4
of 4
pro vyhledávání: '"DDGC Peters"'
Autor:
Willemijn Theelen, O Krijgsman, K Monkhorst, T Kuilman, DDGC Peters, S Cornelissen, M Ligtenberg, SM Willems, JLG Blaauwgeers, CJM van Noesel, DS Peeper, MM van den Heuvel, K Schulze
The authors have removed this preprint from Research Square.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ac60376d516046774498019db5601cb
https://doi.org/10.21203/rs.3.rs-26299/v1
https://doi.org/10.21203/rs.3.rs-26299/v1
Autor:
Dijkstra KK; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Weeber F; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Velds A; Central Genomics Facility, Netherlands Cancer Institute, Amsterdam, Netherlands., Kaing S; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands., Peters DDGC; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands., de Groot DA; Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands., Tesselaar MET; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Voest EE; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, Netherlands.; Oncode Institute, Amsterdam, Netherlands.
Publikováno v:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2021 Mar 11; Vol. 12, pp. 627819. Date of Electronic Publication: 2021 Mar 11 (Print Publication: 2021).
Autor:
Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Postbus 90203, 1006 BE, Amsterdam, The Netherlands. w.theelen@nki.nl., Krijgsman O; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kuilman T; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Neogene Therapeutics, Amsterdam, The Netherlands., Peters DDGC; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Cornelissen S; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Ligtenberg MA; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Willems SM; Department of Pathology, University Medical Centre Groningen, Groningen, The Netherlands., Blaauwgeers JLG; Department of Pathology, OLVG LAB BV, Amsterdam, The Netherlands., van Noesel CJM; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., Schulze K; Oncology Biomarker Development, Genentech Inc, South San Francisco, USA.
Publikováno v:
Journal of translational medicine [J Transl Med] 2020 Jul 03; Vol. 18 (1), pp. 271. Date of Electronic Publication: 2020 Jul 03.
Autor:
Theelen WSME; Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kuilman T; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schulze K; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Zou W; Biostatistics, Genentech Inc., South San Francisco, United States of America., Krijgsman O; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Peters DDGC; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Cornelissen S; Core Facility Molecular Pathology & Biobanking, Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sarma P; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Sumiyoshi T; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Amler LC; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America., Willems SM; Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands., Blaauwgeers JLG; Department of Pathology, OLVG, Amsterdam, The Netherlands., van Noesel CJM; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands., Peeper DS; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Heuvel MM; Department of Pulmonology, Radboud University Medical Center, Nijmegen, The Netherlands., Kowanetz M; Oncology Biomarker Development, Genentech Inc., South San Francisco, United States of America.
Publikováno v:
PloS one [PLoS One] 2019 May 24; Vol. 14 (5), pp. e0216864. Date of Electronic Publication: 2019 May 24 (Print Publication: 2019).